- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Century Therapeutics COO Farid Adrienne verkauft Aktien im Wert von 822 US-Dollar | 2 | Investing.com Deutsch | ||
| 22.01. | 4 Analysts Have This To Say About Century Therapeutics | 4 | Benzinga.com | ||
| 21.01. | Century Therapeutics startet Zelltherapie-Studie für Autoimmunerkrankungen | 2 | Investing.com Deutsch | ||
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.01. | Century Therapeutics launches cell therapy trial for autoimmune diseases | 1 | Investing.com | ||
| 21.01. | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 108 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen | |
| 13.01. | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.12.24 | Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler | 2 | MarketBeat | ||
| 13.12.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.11.24 | Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% | 2 | Benzinga.com | ||
| 06.11.24 | HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 | 4 | MarketBeat | ||
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 149 | GlobeNewswire (Europe) | - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%... ► Artikel lesen | |
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 05.11.24 | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Century Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09.24 | Century Therapeutics Appoints Morgan Conn As CFO | - | RTTNews | ||
| 26.09.24 | Century Therapeutics taps Morgan Conn as CFO | 1 | Seeking Alpha | ||
| 26.09.24 | Century Therapeutics, Inc.: Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer | 184 | GlobeNewswire (Europe) | - Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy... ► Artikel lesen | |
| 26.09.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates | 132 | GlobeNewswire (Europe) | - Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,150 | -0,43 % | Evotec Aktie: Wechselwirkungen im internationalen Kontext | Die Evotec-Aktie verzeichnete am Handelstag einen bemerkenswerten Aufschwung und kletterte im XETRA-Handel um 5,3 Prozent auf 8,97 Euro. Das Handelsvolumen erreichte dabei 475.841 Aktien, wobei das... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,849 | +3,16 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,832 | -7,56 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,688 | +1,47 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,581 | +0,26 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -2,67 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,490 | -0,12 % | Viking Therapeutics Aktie: Einholung von Informationen | Viking Therapeutics befindet sich an einem entscheidenden Punkt, während der Biotechsektor auf ein dynamisches Jahr zusteuert. Die Aktie des Unternehmens brach am Montag um 11,75 Prozent auf 24,49 Euro... ► Artikel lesen | |
| BIO-GATE | 0,755 | -3,82 % | EQS-News: Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr gut" | EQS-News: Bio-Gate AG
/ Schlagwort(e): Studienergebnisse/Sonstiges
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,866 | +3,10 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,460 | +2,04 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,056 | +1,46 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| GALAPAGOS NV | 24,800 | +0,08 % | Galapagos NV: Galapagos to Present at Upcoming Investor Conferences | Mechelen, Belgium; February 24, 2025, 22:01 CET - Galapagos NVBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25... ► Artikel lesen | |
| AFFIMED | 0,900 | -4,26 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,270 | +1,50 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,114 | +0,18 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in March | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in March
03.03.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen |
CENTURY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,629 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.
